文献速递血栓与止血

利用修饰凝血因子V检测蛋白S活性的方法开发

Development of an assay using a modified coagulation factor V to measure protein S activity.
PubMed 文献 · J Thromb Haemost · 2024-09-05

研究设计了一种模拟活化蛋白C底物的重组修饰凝血因子V(FVm),用于定量血浆蛋白S活性,并在160份生物样本库血浆及47例PROS1测序受试者中评价。该FVm裂解法检测蛋白S呈浓度依赖性,与游离蛋白S抗原相关性较弱,且不受利伐沙班干扰。

要点

  • 基于修饰凝血因子V(FVm)裂解的新方法可定量血浆蛋白S活性,呈浓度依赖性。
  • FVm裂解法与游离蛋白S抗原水平相关性相对较弱。
  • 与凝固法不同,FVm裂解法不受血浆中利伐沙班存在的影响。

核心结论

  • 使用FVm底物的检测方法可能比凝固法受干扰更少,能更准确评价血浆蛋白S活性。

研究设计与样本

  • 研究设计了一种模拟活化凝血因子Va的重组修饰凝血因子V(FVm)。
  • 分析了来自日本国立脑心血管中心生物样本库的160份目的性选取的血浆样本。
  • 对47例在FVm裂解法或凝固法中任一活性<60%的受试者进行PROS1全部外显子测序。

主要发现

  • FVm裂解法在混合正常与蛋白S缺乏血浆中呈蛋白S浓度依赖性检测到FVm裂解。
  • FVm裂解法测得的蛋白S活性与游离蛋白S抗原水平相关性相对较弱。
  • 在两种方法活性均<60%的24例受试者中,12例检出非同义变异。
  • 在仅FVm裂解法活性<60%的7例受试者中,2例检出非同义变异。
  • 在仅凝固法活性<60%的16例受试者中,未检出变异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Protein S (PS) is an anticoagulant that functions as a cofactor for activated protein C and the tissue factor pathway inhibitor. PS deficiency is a risk factor for venous thromboembolism. PS activity is commonly measured using clot-based assays involving fibrin and thrombin production, but improvements are needed. OBJECTIVES: To develop a new assay for measuring plasma PS activity by quantifying the amount of activated coagulation factor (F)V cleaved by activated protein C. METHODS: We designed a recombinant, modified FV (FVm) that mimicked FVa. We analyzed 160 purposively selected plasma samples from the Biobank of the National Cerebral and Cardiovascular Center. RESULTS: The assay using mixed normal and PS-deficient plasma detected FVm cleavage in a PS concentration-dependent manner. The correlation between PS activity, measured using the FVm cleavage assay, and free PS antigen levels was relatively weak. We then sequenced all exons of PROS1 from 47 subjects with <60% activity in either the FVm cleavage assay or the clot-based assay. Nonsynonymous variants were identified in 12 of 24 subjects with <60% activity in both assays and in 2 of 7 subjects with <60% activity in the FVm cleavage assay alone. No variants were identified in 16 subjects with <60% activity in the clot-based assay alone. Unlike the clot-based assay, the FVm cleavage assay was not affected by the presence of rivaroxaban in the plasma. CONCLUSION: An assay using the FVm substrate may be less susceptible to interference and provide a more accurate evaluation of plasma PS activity than clot-based assays.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Maruyama K, Kokame K. Development of an assay using a modified coagulation factor V to measure protein S activity. J Thromb Haemost. 2024. PMID: 39243859. doi:10.1016/j.jtha.2024.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。